entinostat has been researched along with Carcinoma, Non-Small Cell Lung in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Entinostat is a selective HDAC inhibitor that has shown anti-neoplastic activity and tolerability in hematologic and solid tumors, including lung cancer." | 2.52 | Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. ( Raez, LE; Rolfo, C; Ruiz, R, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, MJ | 1 |
| Ojha, R | 1 |
| Lin, MH | 1 |
| Liu, YM | 1 |
| Lee, HY | 1 |
| Lin, TE | 1 |
| Hsu, KC | 1 |
| Chang, CY | 1 |
| Chen, MC | 1 |
| Nepali, K | 1 |
| Chang, JY | 1 |
| Liou, JP | 1 |
| Hellmann, MD | 1 |
| Jänne, PA | 1 |
| Opyrchal, M | 1 |
| Hafez, N | 1 |
| Raez, LE | 2 |
| Gabrilovich, DI | 1 |
| Wang, F | 1 |
| Trepel, JB | 1 |
| Lee, MJ | 1 |
| Yuno, A | 1 |
| Lee, S | 1 |
| Brouwer, S | 1 |
| Sankoh, S | 1 |
| Wang, L | 1 |
| Tamang, D | 1 |
| Schmidt, EV | 1 |
| Meyers, ML | 1 |
| Ramalingam, SS | 1 |
| Shum, E | 1 |
| Ordentlich, P | 2 |
| Orillion, A | 1 |
| Hashimoto, A | 1 |
| Damayanti, N | 1 |
| Shen, L | 1 |
| Adelaiye-Ogala, R | 1 |
| Arisa, S | 1 |
| Chintala, S | 1 |
| Kao, C | 1 |
| Elzey, B | 1 |
| Gabrilovich, D | 1 |
| Pili, R | 1 |
| Yokobori, T | 1 |
| Yokoyama, Y | 1 |
| Mogi, A | 1 |
| Endoh, H | 1 |
| Altan, B | 1 |
| Kosaka, T | 1 |
| Yamaki, E | 1 |
| Yajima, T | 1 |
| Tomizawa, K | 1 |
| Azuma, Y | 1 |
| Onozato, R | 1 |
| Miyazaki, T | 1 |
| Tanaka, S | 1 |
| Kuwano, H | 1 |
| Vendetti, FP | 2 |
| Topper, M | 1 |
| Huang, P | 1 |
| Dobromilskaya, I | 1 |
| Easwaran, H | 1 |
| Wrangle, J | 2 |
| Baylin, SB | 2 |
| Poirier, JT | 1 |
| Rudin, CM | 2 |
| Ruiz, R | 1 |
| Rolfo, C | 1 |
| Weintraub, K | 1 |
| Carter, CA | 1 |
| Zeman, K | 1 |
| Day, RM | 1 |
| Richard, P | 1 |
| Oronsky, A | 1 |
| Oronsky, N | 1 |
| Lybeck, M | 1 |
| Scicinski, J | 1 |
| Oronsky, B | 1 |
| Wang, S | 1 |
| Zhu, L | 1 |
| Zuo, W | 1 |
| Zeng, Z | 1 |
| Huang, L | 1 |
| Lin, F | 1 |
| Lin, R | 1 |
| Wang, J | 1 |
| Lu, J | 1 |
| Wang, Q | 1 |
| Lin, L | 1 |
| Dong, H | 1 |
| Wu, W | 1 |
| Zheng, K | 1 |
| Cai, J | 1 |
| Yang, S | 1 |
| Ma, Y | 1 |
| Ye, S | 1 |
| Liu, W | 1 |
| Yu, Y | 1 |
| Tan, J | 1 |
| Liu, B | 2 |
| Song, J | 1 |
| Luan, J | 1 |
| Sun, X | 1 |
| Bai, J | 1 |
| Wang, H | 1 |
| Li, A | 1 |
| Zhang, L | 1 |
| Feng, X | 1 |
| Du, Z | 1 |
| Niesen, MI | 1 |
| Blanck, G | 1 |
| Kakihana, M | 1 |
| Ohira, T | 1 |
| Chan, D | 1 |
| Webster, RB | 1 |
| Kato, H | 1 |
| Drabkin, HA | 1 |
| Gemmill, RM | 1 |
| Witta, SE | 1 |
| Jotte, RM | 1 |
| Konduri, K | 1 |
| Neubauer, MA | 1 |
| Spira, AI | 1 |
| Ruxer, RL | 1 |
| Varella-Garcia, M | 1 |
| Bunn, PA | 1 |
| Hirsch, FR | 1 |
| Juergens, RA | 1 |
| Murphy, SC | 1 |
| Zhao, M | 1 |
| Coleman, B | 1 |
| Sebree, R | 1 |
| Rodgers, K | 1 |
| Hooker, CM | 1 |
| Franco, N | 1 |
| Lee, B | 1 |
| Tsai, S | 1 |
| Delgado, IE | 1 |
| Rudek, MA | 1 |
| Belinsky, SA | 1 |
| Herman, JG | 1 |
| Brock, MV | 1 |
| Nagathihalli, NS | 1 |
| Massion, PP | 1 |
| Gonzalez, AL | 1 |
| Lu, P | 1 |
| Datta, PK | 1 |
| Charrier, C | 1 |
| Roche, J | 1 |
| Gesson, JP | 1 |
| Bertrand, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Color[NCT02437136] | Phase 1/Phase 2 | 196 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer and Men and Women With Progressive Non-Small Cell Lung Cancer[NCT01594398] | Phase 1 | 14 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer[NCT00387465] | Phase 1/Phase 2 | 94 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy[NCT03941496] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2022-10-31 | Withdrawn (stopped due to The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DLT is defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 (NCT00387465)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I - 30mg/m2 Azacitidine | 0 |
| Phase I - 40mg/m2 Azacitidine | 0 |
"Number of participants with decrease in DNA methylation (methylation-signature positive) on Day 10 or Day 29, and either stable disease or objective response (OR) as defined by RECIST 1.0. Per RECIST 1.0, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR is defined as >=30% decrease in the sum of the longest diameter of target lesions, complete response is defined as disappearance of all target lesions; OR=CR+PR." (NCT00387465)
Timeframe: Baseline and days 10 and 29
| Intervention | Participants (Count of Participants) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 8 |
Determined by the method determined by Kaplan and Meier. 95% confidence intervals will be estimated. (NCT00387465)
Timeframe: Up to 1 year
| Intervention | months (Median) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 6.4 |
(NCT00387465)
Timeframe: Day 1
| Intervention | ng*hr/mL (Mean) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 675 |
Maximal concentration (ng/mL) of azacitidine (NCT00387465)
Timeframe: Day 1
| Intervention | ng/mL (Mean) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 468 |
(NCT00387465)
Timeframe: Day 1
| Intervention | hours (Mean) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 1.12 |
Time to maximal concentration of azacitidine in the blood. (NCT00387465)
Timeframe: Day 1
| Intervention | hours (Median) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 0.5 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Determined by the method determined by Kaplan and Meier. 95% confidence intervals will be estimated. (NCT00387465)
Timeframe: Up to 1 year
| Intervention | weeks (Median) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 7.4 |
(NCT00387465)
Timeframe: Day 10 and 17
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Day 10 | Day 17 | |
| Azacitidine 40mg/m2 With Entinostat | 0.84 | 1.10 |
2 reviews available for entinostat and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Epigenesis, Genetic; His | 2015 |
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small | 2016 |
3 trials available for entinostat and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2021 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carc | 2012 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carc | 2012 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carc | 2012 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carc | 2012 |
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Bi | 2011 |
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Bi | 2011 |
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Bi | 2011 |
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Bi | 2011 |
11 other studies available for entinostat and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
Topics: A549 Cells; Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Catalytic Do | 2019 |
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
Topics: Animals; Benzamides; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Disease Models, Animal; | 2017 |
FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Carcinoma, No | 2014 |
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Camptothecin; Carc | 2015 |
Take two: Combining immunotherapy with epigenetic drugs to tackle cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Car | 2016 |
MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DN | 2016 |
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Topics: Animals; Azacitidine; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumo | 2016 |
Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Histone Deacety | 2009 |
Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Blotting, Western; Cadherins; | 2009 |
Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin.
Topics: Acetylation; Antigens, CD; Benzamides; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Movement; Dow | 2012 |
Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; | 2007 |